TL;DRAbstract
Abstract : The aim of this project is preclinical testing of a novel Ras antagonist, farnesylthiosalicylate (FTS in complex with a cyclodextrin (CD) carrier. Ras is involved in estrogen and growth factor signaling in breast cancer cells. inhibition of Ras should prevent growth of breast cancer cells. We have tested FTS-CD against several breast cancer cell lines in vitro and found that: * FTS-CD is effective against estrogen receptor positive breast cancer in vitro. * FTS-CD is effective against Tamoxifen resistant cells in vitro. * FTS-CD interferes with estrogen signaling. * FTS-CD induces profound changes in cell signaling, manifested as increase in apoptosis and decrease in proliferation.
Chat with Paper
AI Agents for this Paper
Abstract : The aim of this project is preclinical testing of a novel Ras antagonist, farnesylthiosalicylate (FTS in complex with a cyclodextrin (CD) carrier. Ras is involved in estrogen and growth factor signaling in breast cancer cells. inhibition of Ras should prevent growth of breast cancer cells. We have tested FTS-CD against several breast cancer cell lines in vitro and found that: * FTS-CD is effective against estrogen receptor positive breast cancer in vitro. * FTS-CD is effective against Tamoxifen resistant cells in vitro. * FTS-CD interferes with estrogen signaling. * FTS-CD induces profound changes in cell signaling, manifested as increase in apoptosis and decrease in proliferation.
Keywords
Chat
Click to start Chat